ANDA vs 505(b)(2) Applications

FDA published guidance addressing the distinctions between Abbreviated New Drug Applications (ANDAs) and 505(b)(2) applications. ANDA pathways apply to generic drugs requiring bioequivalence to reference listed drugs, while 505(b)(2) applies to products relying on existing safety/effectiveness data with differences from the reference product. The guidance clarifies data requirements, approval criteria, and filing considerations for each pathway.

Pharmaceutical manufacturers and drug developers should review this guidance when preparing regulatory submissions to ensure proper pathway selection. Misclassification between ANDA and 505(b)(2) could result in rejected applications or delays. Companies developing generic drugs, hybrid products, or drugs with proprietary modifications will need to assess which pathway aligns with their product characteristics and data availability.